Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer

Trial Details

NCT ID
NCT06642545
Phase
PHASE2
Sponsor
RemeGen Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Disitamab Vedotin
  • RC148
  • Albumin-bound Paclitaxone
  • Toripalimab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Voluntarily agree to participate in the study and sign the informed consent form
  • Stage III unresectable locally advanced or Stage IV metastatic breast cancer.
  • Subjects must be willing and able to provide a tumor tissue block and/or unstained pathology slides, with priority given to the most recent metasta…
  • Invasive breast tumor tissue has been confirmed as HER2 low expression by the central laboratory

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →